# daGOAT-Guided Prevention of Severe aGVHD After Allo-HSCT

> **NCT07588945** · PHASE3 · NOT_YET_RECRUITING · sponsor: **Institute of Hematology & Blood Diseases Hospital, China** · enrollment: 438 (estimated)

## Conditions studied

- Transplant-Related Disorder

## Interventions

- **DRUG:** Ruxolitinib

## Key facts

- **NCT ID:** NCT07588945
- **Lead sponsor:** Institute of Hematology & Blood Diseases Hospital, China
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-06-01
- **Primary completion:** 2027-12-31
- **Final completion:** 2028-06-01
- **Target enrollment:** 438 (ESTIMATED)
- **Last updated:** 2026-05-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07588945

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07588945, "daGOAT-Guided Prevention of Severe aGVHD After Allo-HSCT". Retrieved via AI Analytics 2026-05-21 from https://api.ai-analytics.org/clinical/NCT07588945. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*